Local view for "http://purl.org/linkedpolitics/eu/plenary/2002-10-22-Speech-2-042"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2002-10-22"^^xsd:date2
dcterms:Is Part Of	lp_eu:Medicinal products2
dcterms:Language	"fr"^^xsd:language2
lpv:document identification number	"en.20021022.1.2-042"2
lpv:hasSubsequent	lp_eu:2002-10-22-Speech-2-0432
lpv:speaker	lp:Françoise Grossetête2
lpv:spokenAs	substitute; BUDG (2002-08-29--2004-07-19)3 vice-chair; EPP-ED (2002-03-08--2004-07-19)3 member; Temporary committee on foot and mouth disease (2002-01-17--2002-12-17)3 member; Delegation to the EU-Cyprus Joint Parliamentary Committee (2002-03-07--2004-04-30)3 member; Committee on the Environment, Public Health and Consumer Policy (2002-01-17--2004-07-19)3 unknown; Démocratie libérale (1999-07-20--2002-11-17)3
lpv:translated text	"Mr President, Commissioner, allow me, after having listened to my fellow Members this morning, to draw their attention to a point that I believe to be crucial, which is that of new active substances. I hope, along with the Commission, that marketing authorisations for new active substances are issued by means of the centralised procedure, and I would like to reiterate to my fellow Members, particularly to those from Germany, the example of orphan medicinal products. You will, without doubt, remember that at the beginning of our mandate, we voted in favour of a regulation on orphan medicinal products, which allow us to treat rare conditions. The policy on orphan medicinal products, which is a genuine success at European level, stipulates that all market authorisation applications for these medicinal products shall be issued through the centralised procedure. Given that research in the area of orphan medicinal products is carried out by small and medium-sized companies, it follows that all SMEs can use the marketing authorisation application, under the centralised procedure, managed by the European Agency in London. Your argument in favour of the decentralised procedure in the area of new active substances is therefore unfounded, and has no bearing on our discussion today. Think about that. At tomorrow’s vote, think about what you will say to any of your fellow citizens who asks you what you have done. Have I really voted to provide better health protection? Have I really tried to achieve the essential objective, namely to improve public health? Have I done everything I can and voted in such a way as to achieve this goal? Ladies and gentlemen, I therefore urge you to think carefully about the vote you will take tomorrow. We simply must encourage improvements in the area of health and promote equality amongst citizens in healthcare."@en1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph